© 2026 Sinochem Nanjing Corporation,
All Right Reserved
|
HS Code |
746827 |
As an accredited 7-Bromo-6-Chloro-4-Quinazolinone factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | |
| Shipping | |
| Storage |
Competitive 7-Bromo-6-Chloro-4-Quinazolinone prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please call us at +8615371019725 or mail to admin@sinochem-nanjing.com.
We will respond to you as soon as possible.
Tel: +8615371019725
Email: admin@sinochem-nanjing.com
Flexible payment, competitive price, premium service - Inquire now!
Scientific discovery often comes down to the smallest details. I’ve seen experiments thrive or tumble based on the purities or structural nuances of a compound. That’s why in modern chemical and pharmaceutical laboratories, careful selection of research materials matters. 7-Bromo-6-Chloro-4-Quinazolinone—a quinazolinone derivative—has become a go-to option for teams exploring novel synthetic pathways, drug candidates, and analytical standards.
Quinazolinones hold a special reputation in medicinal chemistry and agricultural innovation. This class of compounds has led the way in producing molecules for anti-cancer drugs, anti-inflammatory agents, and even herbicidal frameworks. 7-Bromo-6-Chloro-4-Quinazolinone stands out due to its halogenated backbone. Adding bromine at the 7-position and chlorine at the 6-position changes chemical reactivity in useful ways. These changes open up options for selective substitutions or downstream functionalization in synthetic schemes.
Labs don’t just look for a molecule with a name—they need precision. Synthesizing advanced quinazolinones like this one involves efficient, reproducible routes. We’re talking about repeated purification, demanding analytical checks, and ensuring the lot actually meets expectations. This compound isn’t just a technical curiosity; it’s part of a toolkit pushing frontline research forward.
Spotting a high-grade sample of 7-Bromo-6-Chloro-4-Quinazolinone is all about consistency. The material generally comes as an off-white or pale yellow crystalline powder. The appearance might seem trivial, but any unexpected color or texture sends a warning bell. The molecular weight falls into a range that keeps it practical for bench-scale applications but allows for larger scale-up if a research project heads that direction.
Dissolving the powder in organic solvents like dimethyl sulfoxide, DMF, or even low polarity options gives researchers flexibility. Depending on the goal—NMR analysis, recrystallization, liquid chromatography—you want a reliable profile. Even the way the sample behaves on TLC, HPLC, or melting point analysis provides assurance that the product is what’s on the label.
The halogenation pattern (with both bromine and chlorine) is more than just a decorative touch. It changes the electron density across the aromatic system. For a chemist, this means the molecule can head down pathways that less-substituted quinazolinones cannot. It’s not just about reactivity, though; these modifications may influence solubility, crystal habit, and handling, from weighing small amounts to integrating into multi-step synthesis routes.
Quinazolinone derivatives have shaped the direction of targeted therapies, enzyme inhibitors, and agricultural treatments. The lure of 7-Bromo-6-Chloro-4-Quinazolinone comes from its versatility as both a research target and building block. In my experience, halogenated analogs unlock routes for further substitution, often simplifying a synthetic plan. That translates into fewer steps, less waste, and streamlined purification. Those improvements don’t just trim costs—they save time. Time is what keeps a promising idea moving forward in crowded research pipelines.
Research into anti-tumor, antimicrobial, and enzyme inhibitory properties of related quinazolinones has picked up over the last decade. By starting out with a pre-halogenated molecule, investigators avoid cumbersome, low-yield reactions late in a synthesis. Using 7-Bromo-6-Chloro-4-Quinazolinone means you skip over some classic bottlenecks. I’ve noticed this effect especially when scaling syntheses or when library generation needs to be rapid and broad.
Older, non-halogenated quinazolinones remain widely used, but they don’t offer the same mix of reactivity and selectivity. The bromine and chlorine atoms here set up unique cross-coupling reactions, like those mediated by palladium catalysts. Chemists working on new kinase inhibitors, for instance, can design linkers and side chains that attach at those functionalized positions. That’s a rare level of precision without laborious protecting group strategies.
There’s also a more practical upside. Handling a stable, crystalline compound is easier in daily lab work compared to sticky, oily, or deliquescent materials, which some analogs tend to become. I’ve run into far fewer storage and weighing frustrations with solid-state halogenated quinazolinones than with their less robust cousins.
Reliable research depends on consistency, not chance. I’ve seen well-funded projects falter because key intermediates or standards failed to meet assay purity. Quality control goes beyond marketing—look for independent third-party testing, spectroscopic data (proton, carbon NMR, HRMS), and chromatography profiles. Analytical documentation is a sign that your batch has been vetted. When a project hangs on one experiment, uncertainties have to be eliminated at the source.
Working with reputable suppliers means fewer surprises over the course of multi-year projects. A single off-batch might throw months of work into question. Mitigating those risks begins with picking materials that come with full transparency—no shortcuts. Each time my group switched to a higher grade of 7-Bromo-6-Chloro-4-Quinazolinone with robust documentation, reproducibility improved and results stood up to peer review.
Teams diving into kinase pathways, nucleic acid interactions, or agricultural screens need flexible intermediates. 7-Bromo-6-Chloro-4-Quinazolinone works as an anchor in these efforts: its halogenation pattern brings a dual advantage. Bromine on the 7-position often opens doors for Suzuki or Buchwald-Hartwig couplings, while the chlorine on the 6-position adjusts electrophilicity, directly influencing selectivity in certain reactions.
In medicinal chemistry, scaffold design can get complex quickly. Substituted quinazolinones act as platform structures, allowing rapid diversification. By starting with this compound, scientists can attach aryl, alkyl, or heterocyclic moieties, optimizing bioactivity in a modular way. I’ve seen these approaches slash development time for early-stage probe molecules or pre-clinical candidates. That efficiency isn’t just good science: it’s good business.
Every research setting has its safety culture, shaped not just by protocols, but by the nature of the materials in use. 7-Bromo-6-Chloro-4-Quinazolinone, like many fine chemicals, asks for careful handling. Stable at ambient conditions, this powder won’t evaporate or degrade quickly, which makes routine storage and weighing less stressful. That cloud of uncertainty that comes with low-melting solids, oils, or compounds prone to decomposition simply doesn’t appear as often here.
Laboratories developing next-generation pharmaceuticals or crop protectants now face greater scrutiny over waste and exposure. Using well-characterized, stable intermediates can lower the risk of off-gassing or accidental spills. Disposing of spent solvent and solid residue may still need specialized waste streams, given the halogens, but good lab stewardship lessens the environmental impact overall.
Not every halogenated quinazolinone plays the same role in synthesis. Some products offer fluorinated or iodinated variants, which can add another layer of functionality (or cost). 7-Bromo-6-Chloro-4-Quinazolinone finds a balance between price, usability, and downstream reaction utility. Its molecular weight sits in an optimal window for medicinal chemistry, hit discovery programs, and reaction optimization studies.
If a project calls for heavier halogens or perfluorinated analogs, costs and synthetic complexity can run up quickly. For routine medicinal chemistry campaigns or probe synthesis, balancing yield, ease of scale-up, and minimal regulatory hurdles tips the scales toward this bromo-chloro variant. My team found reaction yields with this compound often tracked higher, and scale-up steps could go forward without additional purification rounds.
New technologies and tough disease targets are the main drivers of innovation. 7-Bromo-6-Chloro-4-Quinazolinone supports these efforts by allowing direct, high-yield routes to final active ingredients or advanced intermediates. Reducing multistep syntheses is more than a workflow improvement—it cuts cumulative waste, lowers exposure to hazardous reagents, and improves alignment with environmental targets.
In collaborative projects, smooth scale-up from gram to kilogram matters. Handling predictable, clean, halogenated intermediates keeps timelines reliable and budgets on track. The direct substitution patterns available here ease the transition from discovery chemistry to process development. Every time my team has integrated this molecule into our workflow, technical hiccups decreased and output stayed consistent, even with shifting project scopes.
Global trends push both academic and industrial labs to rethink their approach to resource management. That includes solvents, energy use, and the selection of starting materials. 7-Bromo-6-Chloro-4-Quinazolinone aligns with these efforts by offering clear substitution points for green chemistry interventions—direct couplings cut down on protecting group strategies and minimize auxiliary waste.
Committing to standards isn’t just a matter of ticking regulatory boxes. It brings credibility, competitive advantage, and a chance to lead rather than chase sustainable chemistry practices. Reducing synthetic steps, simplifying purification, and recycling solvents only work well when your intermediates play along. Our experience showed that shifting to cleanly halogenated quinazolinones made it easier to pass internal audits and third-party reviews on sustainability practices.
Every medicinal chemistry campaign counts on core building blocks that support rapid diversification. Take 7-Bromo-6-Chloro-4-Quinazolinone: it sits at the intersection of electronic tuning and ease of further derivatization. The presence of both bromine and chlorine fine-tunes selectivity, making it easier to attach payloads or functional groups required for biological activity.
Set against monohalogenated or unsubstituted analogs, this dual-halogen approach stands out. More than once, colleagues have remarked on how much time is saved by targeting the reactive positions directly, skipping labor-intensive halogenation stages partway through a synthesis. It adds up, especially during SAR (structure-activity relationship) studies that require dozens of parallel analogs for screening.
I’ve seen projects where inconsistent materials caused cascading delays. Low-purity intermediates or unknown polymorphs of crucial building blocks introduce headaches ranging from botched analytical runs to regulatory headaches. Moving towards well-characterized variants—like 7-Bromo-6-Chloro-4-Quinazolinone, with consistent solid-state and purity profiles—slashed troubleshooting time on HPLC and stability testing in our group.
Put simply, high-quality, consistently pure materials promote smoother progress. Fewer repeat syntheses. Less downtime. In my experience, a small investment up front for quality saves meaningful resources during scale-up and regulatory submission.
Drug discovery and advanced materials research thrive in a climate of transparency, collaboration, and incremental progress. Working with robust intermediates like 7-Bromo-6-Chloro-4-Quinazolinone cuts down on “unknown unknowns” during the project lifecycle. I’ve watched as less time spent on troubleshooting meant more attention for genuine breakthroughs—selective inhibitors, diagnostic probes, or even new modes of action for crops or environmental applications.
Bringing this level of quality and reactivity to a research program is more than a convenience. For labs required to share data and materials across international teams or consortia, reproducibility and reliable batch documentation remove barriers to open science.
Every so often, the tools that shape research take a quiet leap. 7-Bromo-6-Chloro-4-Quinazolinone typifies one such advance—delivering on both chemical flexibility and bench reliability. New target classes in medicinal chemistry, focused SAR studies, next-generation crop protectants, or advanced material platforms all draw benefit from high-grade, selectively halogenated quinazolinones.
Looking back, the most frustrating roadblocks in research rarely involved a lack of creativity—they came from unpredictable results, batch failures, and synthetic trickiness. The straightforward handling, clean reactivity, and robust purity of this compound have made a difference time and again, letting scientists devote more time to problem solving, not troubleshooting.
The right building blocks make the difference between incremental progress and real breakthroughs. In fields where timing is crucial, regulatory pressures grow, and budgets demand smarter decision-making, crystal-clear advantages like stable supply chains, full documentation, and reliable batch profiles can become a deciding factor.
7-Bromo-6-Chloro-4-Quinazolinone helps bring certainty and flexibility where they’re needed most. As targeted chemistry, sustainability, and cross-team collaboration become hallmarks of contemporary research, choosing robust, versatile intermediates remains a smart move for anyone serious about innovation.
